Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
Nature Medicine·
- DOI
- 10.1038/s41591-022-02090-w
- PMID
- 36257333
- PMCID
- PMC9873555
- OpenAlex
- W4306721676
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
These observations address knowledge gaps surrounding authorized MVA-BN deployment during a recently declared international health emergency by quantifying early immune responses.
Structured evidence summary
Research question
The study evaluates whether the MVA-BN vaccine generates measurable monkeypox virus-neutralizing antibodies in healthy adults without prior poxvirus exposure.
Study design
This research conducts an immunological comparison of antibody titers across multiple vaccination protocols, including a standard two-dose series, a reduced-dose approach, and a subsequent booster administration.
Population and setting
The analysis centers on healthy participants lacking previous viral priming, though precise demographic or geographic characteristics are not detailed in the provided metadata.
Main findings
A conventional two-dose MVA-BN regimen yielded comparatively modest neutralizing antibody concentrations in unexposed individuals. Introducing a third dose substantially elevated these measurements, whereas a fractionated dosing strategy produced lower values. The clinical relevance of these immune markers remains undetermined.
Public-health relevance
These observations address knowledge gaps surrounding authorized MVA-BN deployment during a recently declared international health emergency by quantifying early immune responses.
Important limitations
The provided text lacks explicit methodological constraints or sample size disclosures. Therefore, this summary depends entirely on the supplied abstract and bibliographic records, requiring access to the complete manuscript for rigorous appraisal. Furthermore, the investigation tracks laboratory immune markers rather than direct disease prevention outcomes.
GIDS interpretation
This record contributes foundational immunogenicity data pertinent to orthopoxvirus preparedness literature. Its classification under vaccination and outbreak investigation categories indicates potential utility for scholars monitoring historical vaccine performance metrics during recent zoonotic periods.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.